Cryptotanshinone, an orally bioactive herbal compound from D anshen, attenuates atherosclerosis in apolipoprotein E ‐deficient mice: role of lectin‐like oxidized LDL receptor‐1 ( LOX ‐1)
Zhiping Liu, Suowen Xu, Xiaoyang Huang, Jiaojiao Wang, Si Gao, Hong Li, Changhua Zhou, Jiantao Ye et al.. British Journal of Pharmacology, 2015-02-27
Topic: Gut, metabolism and diet
CTS significantly attenuated atherosclerotic plaque formation and enhanced plaque stability in ApoE −/− mice by inhibiting the expression of lectin‐like ox LDL receptor‐1 ( LOX ‐1) and MMP ‐9, as well as inhibiting reactive oxygen species ( ROS ) generation and NF‐κB activation. CTS treatment significantly decreased the levels of serum pro‐inflammatory mediators without altering the serum lipid profile. In vitro , CTS decreased ox LDL ‐induced LOX ‐1 m RNA and protein expression and, thereby, inhibited LOX ‐1‐mediated adhesion of monocytes to HUVEC s, by reducing the expression of adhesion molecules (intracellular adhesion molecule 1 and vascular cellular adhesion molecule 1). Furthermore, CTS inhibited NADPH oxidase subunit 4 ( NOX 4)‐mediated ROS generation and consequent activation of NF‐κB in HUVEC s. Conclusions and CTS was shown to have anti‐atherosclerotic activity, which was mediated through inhibition of the LOX ‐1‐mediated signalling pathway. This suggests that CTS is a vasculoprotective drug that has potential therapeutic value for the clinical treatment of atherosclerotic cardiovascular diseases. Linked Articles: This article is part of a themed section on Chinese Innovation in Cardiovascular Drug Discovery. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-23
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Liu, Z., Xu, S., Huang, X., Wang, J., Gao, S., Li, H., et al. (2015). Cryptotanshinone, an orally bioactive herbal compound from D anshen, attenuates atherosclerosis in apolipoprotein E ‐deficient mice: role of lectin‐like oxidized LDL receptor‐1 ( LOX ‐1). British Journal of Pharmacology. https://doi.org/10.1111/bph.13068
Vancouver
Liu Z, Xu S, Huang X, Wang J, Gao S, Li H, et al. Cryptotanshinone, an orally bioactive herbal compound from D anshen, attenuates atherosclerosis in apolipoprotein E ‐deficient mice: role of lectin‐like oxidized LDL receptor‐1 ( LOX ‐1). British Journal of Pharmacology. 2015. doi:10.1111/bph.13068.
BibTeX
@article{liu2015-77afde44,
author = {Liu, Zhiping and Xu, Suowen and Huang, Xiaoyang and Wang, Jiaojiao and Gao, Si and Li, Hong and Zhou, Changhua and Ye, Jiantao and others},
title = {{Cryptotanshinone, an orally bioactive herbal compound from D anshen, attenuates atherosclerosis in apolipoprotein E ‐deficient mice: role of lectin‐like oxidized LDL receptor‐1 ( LOX ‐1)}},
journal = {British Journal of Pharmacology},
year = {2015},
doi = {10.1111/bph.13068},
url = {https://doi.org/10.1111/bph.13068}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- CTS significantly attenuated atherosclerotic plaque formation and enhanced plaque stability in ApoE −/− mice by inhibiting the expression of lectin‐like ox LDL receptor‐1 ( LOX ‐1) and MMP ‐9, as well as inhibiting reactive oxygen species ( ROS ) generation and NF‐κB activation.
- CTS treatment significantly decreased the levels of serum pro‐inflammatory mediators without altering the serum lipid profile.
- In vitro , CTS decreased ox LDL ‐induced LOX ‐1 m RNA and protein expression and, thereby, inhibited LOX ‐1‐mediated adhesion of monocytes to HUVEC s, by reducing the expression of adhesion molecules (intracellular adhesion molecule 1 and vascular cellular adhesion molecule 1).
- Furthermore, CTS inhibited NADPH oxidase subunit 4 ( NOX 4)‐mediated ROS generation and consequent activation of NF‐κB in HUVEC s.
- Conclusions and CTS was shown to have anti‐atherosclerotic activity, which was mediated through inhibition of the LOX ‐1‐mediated signalling pathway.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 20 of the 56 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (British Journal of Pharmacology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mice”) — scores zero |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 20 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 20 of the 56 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Genetics
Also in Genetics
173 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.